Lhasa Limited shared knowledge shared progress

Archive

This is a library of Lhasa's blog articles. 

  • 10 tips 
for controlling 
your potentially mutagenic impurities outside the lab.
    Clock: less than 5 minutesless than 5 minutes

    10 tips for controlling your potentially mutagenic impurities outside the lab

    Many readers of this blog will be aware of the threat posed by potentially mutagenic impurities within drug substance synthesis. Such impurities often arise from reagents which are critical to the synthesis therefore this impurity-related threat is unavoidable.

    As such, there is a need to assess the risk posed by mutagenic impurities.

    30 June 2021

  • 20 tips for nitrosamine impurity assessment

    20 tips for nitrosamine impurity assessment

    Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!

    05 August 2021

  • A day in the life of a Mirabilis Scientist at Lhasa Limited
    Clock: less than 5 minutesless than 5 minutes

    A day in the life of a Scientist at Lhasa Limited

    Discover a day in the life of a Mirabilis Research Scientist at Lhasa Limited! 

    28 May 2021

  • Accessing vital sources of 
long-term carcinogenicity study data 
- Discussing the recent LCDB release features in more detail
    Clock: 5 minutes5 minutes

    Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database

    In this blog piece, we explore in more detail, the features of the recent release and how they will benefit LCDB users.

    12 July 2021

  • Collaboration Innovation Working together data sharing
    Clock: less than 5 minutesless than 5 minutes

    Anticipating and supporting the needs of our members

    As a member-based organisation, anticipating and supporting the needs of our members is critical. 

    31 July 2020

  • image portraying data sharing and two ssystems coming together
    Clock: 5 minutes5 minutes

    Comparing CPDB and Lhasa TD50 values in the Lhasa Carcinogenicity Database

    For many years the Carcinogenic Potency Database (CPDB)1, created by Lois Gold and her team, was an important source of long-term carcinogenicity study data. However, as the database had stopped being updated from 2007, Lhasa moved to safeguard the data by providing ongoing access through a freely available interface; the Lhasa Carcinogenicity Database (LCDB)2. The LCDB was released in 2016 and has since been updated with additional data from the National Toxicology Program (NTP)3, increasing the data set to 7,745 studies covering 1,726 chemical substances. A recent update has also facilitated greater ease of access by enabling substructure and similarity-based structure queries.

    08 December 2020

  • How Derek Nexus and Sarah Nexus meet the 5 OECD principles
    Clock: less than 5 minutesless than 5 minutes

    How Derek Nexus and Sarah Nexus meet the 5 OECD principles

    In this article, we discuss how Derek Nexus and Sarah Nexus meet the 5 OECD principles.

    30 November 2021

  • How to make mutagenicity assessment a simpler task blog image
    Clock: less than 5 minutesless than 5 minutes

    How to make mutagenicity assessment a simpler task

    A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

    Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!

    15 September 2021

  • Expert Review Magnifying Glass Results
    Clock: 10 minutes10 minutes

    Human review of in silico predictions of toxicity

    The speed by which models for toxicity prediction can be built and the accuracy with which they can make predictions, have both improved greatly in recent years as a result of advances in technology, mechanistic understanding and access to data.

    21 May 2020

  • Teamwork blog shutterstock
    Clock: less than 5 minutesless than 5 minutes

    It Takes a Team to Build an Adverse Outcome Pathway

    The saying goes, “It takes a village to raise a child”. This sentiment can be translated to the work we do at Lhasa Limited, particularly to the work which we put into building Adverse Outcome Pathways (AOPs). To echo the sentiment in Chris Barber’s previous blog post, The challenge of building QSAR models; it is easy to build an AOP, harder to build a useful AOP, and as for building an AOP you can trust? It takes a team.

    Read about how we are building adverse outcome pathways (AOPs) at Lhasa in this blog post written by Dr. Susanne Stalford, Senior Scientist at Lhasa.

     

    30 September 2020

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.